Medical School · Year 2 · Gastrointestinal · includes a quiz and discussion video

Lecture 12: Biliary Diseases

Unit 2.2: Gastrointestinal System

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the pathophysiology and types of gallstone disease
2. Explain the clinical presentation and management of biliary colic and acute cholecystitis
3. Describe choledocholithiasis and its complications
4. Explain cholangitis and its management
5. Describe biliary tract malignancies
6. Explain the approach to the patient with jaundice

Gallstone Disease Overview

Gallstone disease affects ten to fifteen percent of adults in Western populations and represents one of the most common reasons for abdominal surgery. Understanding the pathophysiology, risk factors, and clinical manifestations enables appropriate diagnosis and management.

Epidemiologically, gallstone prevalence increases with age and demonstrates significant demographic variation. Women develop gallstones two to three times more frequently than men. Ethnic variation is striking, with highest prevalence among Native Americans and Hispanics. Prevalence increases progressively with age, reaching thirty percent in individuals over sixty years.

Risk factors for gallstones are classically summarized by the "4 F's" mnemonic: female, forty, fertile (multiparous), and fat (obese). However, numerous additional factors contribute. Female sex increases risk through estrogen effects that enhance cholesterol secretion into bile. Advancing age promotes gallstone formation through multiple mechanisms. Multiparity increases risk because pregnancy reduces gallbladder motility and increases biliary cholesterol saturation. Obesity dramatically elevates risk through increased hepatic cholesterol secretion. Paradoxically, rapid weight loss also precipitates gallstones by mobilizing cholesterol faster than bile acid synthesis can compensate. Diabetes mellitus impairs gallbladder motility. Cirrhosis increases black pigment stones through impaired bilirubin conjugation. Ileal disease or resection depletes the bile acid pool. Certain medications including estrogen, fibrates, and octreotide promote stone formation.

Gallstones are classified by composition into three main types. Cholesterol stones, comprising seventy-five to eighty percent of gallstones in Western countries, form when bile becomes supersaturated with cholesterol relative to bile acids and phospholipids. These stones are typically yellow-green, may be single or multiple, and are often radiolucent on plain radiography. Black pigment stones, representing fifteen to twenty percent, consist primarily of calcium bilirubinate and form in conditions causing increased bilirubin load (chronic hemolysis) or impaired conjugation (cirrhosis). These stones are small, dark, and often multiple. Brown pigment stones comprise less than five percent and form in the setting of biliary infection with bacteria that deconjugate bilirubin; they are typically found in bile ducts rather than the gallbladder.

Cholesterol stone pathophysiology involves three critical factors. Supersaturation occurs when the cholesterol concentration in bile exceeds the solubilizing capacity of bile acids and phospholipids. Nucleation describes the precipitation of cholesterol crystals from supersaturated bile, accelerated by mucin and other pronucleating factors. Gallbladder hypomotility allows crystals to aggregate rather than being expelled with bile, enabling stone growth.

<image>Panel A: Epidemiology panel with Western prevalence (10-15%), male versus female comparison, and ethnic variation chart with highest rates in Native Americans. Panel B: Risk factors diagram with central 4 F's (female, forty, fertile, fat) and additional factors including rapid weight loss, diabetes, cirrhosis, ileal disease, and medications. Panel C: Three gallstone types illustrated side by side showing cholesterol stones (yellow-green, radiolucent), black pigment stones (small, dark, hemolysis-associated), and brown pigment stones (soft, infected, found in ducts). Panel D: Cholesterol stone formation pathophysiology as three-step process of supersaturation, nucleation, and gallbladder hypomotility.</image>

Biliary Colic

Biliary colic occurs when a gallstone transiently obstructs the cystic duct during gallbladder contraction, causing visceral pain that resolves when the stone disimpacts. Despite its name, the pain is not truly colicky (waxing and waning) but rather steady and severe.

The pathophysiology involves gallbladder contraction against an obstructed outflow. Following a fatty meal, cholecystokinin triggers gallbladder contraction to release bile. If a stone lodges in the cystic duct or gallbladder neck (Hartmann's pouch), the distended gallbladder generates intense visceral pain. When the stone dislodges or falls back into the gallbladder body, obstruction resolves and pain subsides. Episodes typically last thirty minutes to six hours; pain persisting beyond six hours suggests progression to acute cholecystitis.

Clinical presentation follows a recognizable pattern. Pain localizes to the right upper quadrant or epigastrium and often radiates to the right scapula or shoulder, reflecting the shared innervation of the gallbladder and right phrenic nerve. Fatty meals classically trigger episodes by stimulating CCK release and gallbladder contraction. Nausea and vomiting frequently accompany the pain. Importantly, patients are afebrile and lack peritoneal signs because no inflammation is present. Physical examination between episodes is typically normal.

Diagnosis relies primarily on clinical history supported by ultrasound findings. Laboratory tests are characteristically normal, as there is no inflammation (no leukocytosis) and no obstruction of the common bile duct (normal bilirubin and liver enzymes). Transabdominal ultrasound demonstrates gallstones, which appear as echogenic foci with posterior acoustic shadowing. The gallbladder wall remains thin (less than 3 mm), and no pericholecystic fluid is present, distinguishing biliary colic from cholecystitis.

Management of symptomatic gallstones centers on elective cholecystectomy, which eliminates the source of future episodes and prevents progression to more serious complications. Laparoscopic cholecystectomy has become the standard approach, offering shorter hospital stay and faster recovery than open surgery. Medical dissolution therapy with ursodeoxycholic acid can dissolve small cholesterol stones in selected patients unwilling or unable to undergo surgery, but recurrence rates are high and treatment requires months to years. Expectant management carries an annual risk of two to three percent for developing complications, making watchful waiting reasonable in asymptomatic patients but less advisable once symptoms occur.

Asymptomatic gallstones, discovered incidentally on imaging, generally warrant observation rather than intervention. However, certain situations favor prophylactic cholecystectomy: porcelain gallbladder (calcified wall, associated with carcinoma), stones greater than three centimeters (increased cancer risk), and patients undergoing bariatric surgery or awaiting organ transplantation.

<image>Panel A: Pathophysiology illustration of fat ingestion triggering CCK release, gallbladder contraction against a stone in the cystic duct, visceral distension causing pain, and stone dislodgement with resolution over 30 minutes to 6 hours. Panel B: Clinical presentation showing RUQ and epigastric pain with radiation to right scapula, fatty meal triggers, nausea and vomiting, and absence of fever or peritonitis. Panel C: Ultrasound appearance of gallstones as echogenic foci with acoustic shadowing, thin gallbladder wall (less than 3 mm), and no pericholecystic fluid. Panel D: Management algorithm for symptomatic stones (elective laparoscopic cholecystectomy, UDCA, or observation) and asymptomatic stones (observe except porcelain gallbladder, large stones, or surgical candidates).</image>

Acute Cholecystitis

Acute cholecystitis develops when persistent gallstone impaction in the cystic duct causes sustained gallbladder distension, leading to wall inflammation. This represents a surgical emergency requiring prompt recognition and management.

The pathophysiology progresses through predictable stages. A gallstone impacts in the cystic duct or gallbladder neck and fails to disimpact spontaneously. Continued gallbladder secretion against the obstruction causes progressive distension. Wall ischemia develops from increased intraluminal pressure compressing mucosal blood vessels. The initial inflammation is sterile (chemical cholecystitis), but secondary bacterial infection occurs in approximately fifty percent of cases as bacteria translocate from the gut or ascend from the bile duct. Without treatment, the process may progress to gangrenous cholecystitis, perforation, or abscess formation.

Clinical features distinguish cholecystitis from simple biliary colic. Pain persists beyond six hours and steadily worsens rather than resolving. Fever develops, typically low-grade initially but potentially spiking with bacterial superinfection. Murphy's sign, the hallmark physical finding, consists of inspiratory arrest during palpation of the right upper quadrant as the descending diaphragm brings the inflamed gallbladder into contact with the examining hand. Referred pain to the right shoulder occurs through phrenic nerve involvement. Laboratory findings demonstrate leukocytosis, and mild elevation of liver enzymes and bilirubin may occur from inflammatory edema affecting the adjacent bile duct, though marked elevation suggests choledocholithiasis.

Diagnosis employs imaging to confirm clinical suspicion. Transabdominal ultrasound serves as the first-line study, demonstrating gallstones along with findings indicative of inflammation: wall thickening exceeding 3 mm, pericholecystic fluid, and a positive sonographic Murphy's sign (focal tenderness when the transducer compresses directly over the gallbladder). Hepatobiliary iminodiacetic acid (HIDA) scan may be used when ultrasound is equivocal; failure of tracer to fill the gallbladder indicates cystic duct obstruction, highly sensitive for cholecystitis. CT scanning provides better evaluation of complicated disease including perforation, abscess, or gangrenous changes.

The Tokyo Guidelines provide a severity grading system that guides management. Grade I (mild) cholecystitis occurs in healthy patients with mild local inflammation and no organ dysfunction. Grade II (moderate) involves marked local inflammation (leukocytosis exceeding 18,000, palpable mass, duration over 72 hours, or marked local inflammation on imaging) but without organ dysfunction. Grade III (severe) includes any evidence of organ dysfunction such as hypotension, altered mental status, respiratory failure, or acute kidney injury.

Treatment involves supportive care and source control. Initial management includes intravenous fluids, nothing by mouth, and empiric antibiotics covering enteric gram-negative organisms and anaerobes (such as ceftriaxone plus metronidazole or piperacillin-tazobactam). Early laparoscopic cholecystectomy within 72 hours of symptom onset is recommended for Grade I disease, as surgery during this window has comparable outcomes to delayed surgery and avoids prolonged hospitalization and recurrence risk. Grade II disease may undergo early surgery or initial stabilization followed by interval cholecystectomy, depending on surgical expertise and patient factors. Grade III disease typically requires initial percutaneous cholecystostomy to decompress the gallbladder, with cholecystectomy performed after patient stabilization.

<image>Panel A: Pathophysiology timeline from stone impaction through progressive distension, wall ischemia, bacterial superinfection (50% of cases), and potential complications (gangrene, perforation). Panel B: Clinical features comparison table of biliary colic versus cholecystitis showing differences in pain duration, fever, Murphy's sign, leukocytosis, and treatment. Panel C: Imaging findings including ultrasound with wall thickening (greater than 3 mm), pericholecystic fluid, sonographic Murphy's sign, and HIDA scan with gallbladder non-visualization. Panel D: Tokyo Guidelines treatment algorithm for Grade I (early cholecystectomy within 72 hours), Grade II (early or interval surgery), and Grade III (percutaneous cholecystostomy then delayed surgery).</image>

Complications of Cholecystitis

Delayed or inadequate treatment of acute cholecystitis can lead to several serious complications, each with distinct clinical features and management requirements.

Gangrenous cholecystitis represents gallbladder wall necrosis from ischemia and bacterial invasion. Risk factors include advanced age, diabetes mellitus, and delayed presentation. Clinical clues suggesting gangrenous transformation include disproportionate illness severity relative to examination findings (the gangrenous wall becomes denervated, reducing Murphy's sign sensitivity), persistent fever despite antibiotics, and cardiovascular instability. CT imaging may demonstrate wall defects, intraluminal membranes representing sloughed mucosa, or lack of wall enhancement with intravenous contrast indicating devitalized tissue. Management requires urgent surgical intervention given the high risk of perforation.

Emphysematous cholecystitis is a life-threatening variant caused by gas-forming organisms, typically Clostridium perfringens, Escherichia coli, or other enteric bacteria. This condition occurs most commonly in diabetic patients and elderly men. Air within the gallbladder wall or lumen creates characteristic findings on plain radiography or CT scanning. The presentation is often more severe than ordinary cholecystitis, with rapid clinical deterioration. Emergency cholecystectomy combined with broad-spectrum antibiotics is mandatory.

Gallbladder perforation may be contained (forming a pericholecystic abscess) or free (causing biliary peritonitis). Contained perforation presents with persistent symptoms despite treatment, with imaging revealing a localized fluid collection. Free perforation produces sudden clinical deterioration with generalized peritonitis. Surgical exploration with cholecystectomy and peritoneal lavage is required.

Cholecystoenteric fistula and gallstone ileus develop when chronic inflammation causes the gallbladder to adhere to adjacent bowel (usually duodenum), and a large gallstone erodes through both walls into the intestinal lumen. The stone migrates distally until it reaches a narrow point, typically the ileocecal valve, where it causes mechanical small bowel obstruction. Rigler's triad describes the classic radiographic findings: pneumobilia (air in the biliary tree), small bowel obstruction, and an ectopic calcified gallstone. Treatment involves enterotomy with stone extraction; cholecystectomy may be performed simultaneously or deferred depending on patient stability.

Mirizzi syndrome occurs when a stone impacted in the cystic duct or gallbladder neck externally compresses the adjacent common hepatic duct, causing obstructive jaundice. Patients present with jaundice and cholangitis-like features. MRCP or ERCP reveals the characteristic extrinsic compression. Surgical management can be technically challenging and may require bile duct reconstruction.

<image>Panel A: Four cholecystitis complications illustrated showing gangrenous cholecystitis with wall necrosis, emphysematous cholecystitis with gas on CT, gallbladder perforation (contained versus free), and Mirizzi syndrome with cystic duct stone compressing the common hepatic duct. Panel B: Gallstone ileus sequence from cholecystoenteric fistula formation through large stone migration and impaction at the ileocecal valve. Panel C: Rigler's triad radiographic findings including pneumobilia, dilated small bowel loops, and ectopic calcified gallstone. Panel D: Surgical management summary for each complication with urgency indicators and operative approaches.</image>

Choledocholithiasis

Choledocholithiasis refers to the presence of gallstones within the common bile duct. These stones may form primarily within the duct (primary choledocholithiasis, associated with biliary stasis and infection) or, more commonly, pass from the gallbladder (secondary choledocholithiasis). Approximately ten to fifteen percent of patients with symptomatic gallstones have concurrent common bile duct stones.

Clinical presentation varies considerably. Some patients are entirely asymptomatic, with stones discovered incidentally during imaging or cholecystectomy. Symptomatic patients may experience biliary colic as stones intermittently obstruct the duct. Jaundice develops when obstruction is sustained, producing conjugated hyperbilirubinemia. Cholangitis occurs when obstruction allows bacterial infection of the biliary tree. Gallstone pancreatitis results when a stone transiently or persistently impacts at the ampulla, obstructing the pancreatic duct.

Laboratory findings reflect biliary obstruction. Conjugated (direct) bilirubin elevation predominates. Alkaline phosphatase and gamma-glutamyl transferase rise markedly, reflecting cholestasis. Aminotransferases may elevate modestly from backpressure effects, though marked elevation (greater than 1000 U/L) suggests superimposed hepatocellular injury or recent stone passage with transient obstruction.

Diagnosis employs various imaging modalities with different characteristics. Transabdominal ultrasound demonstrates gallstones and may show common bile duct dilation (greater than 6 mm, or greater than 10 mm in patients who have undergone cholecystectomy), but visualizes duct stones in only fifty to eighty percent of cases due to overlying bowel gas. Magnetic resonance cholangiopancreatography (MRCP) provides excellent non-invasive visualization of the biliary tree with sensitivity exceeding ninety percent for detecting duct stones. Endoscopic ultrasound offers similar accuracy and may be preferred when therapeutic intervention is anticipated. Endoscopic retrograde cholangiopancreatography (ERCP) remains the gold standard for both diagnosis and treatment but carries procedural risks including pancreatitis, perforation, and bleeding, so it is reserved for cases where therapeutic intervention is required.

Management employs ERCP with sphincterotomy and stone extraction as the primary therapeutic approach. Endoscopic sphincterotomy divides the sphincter of Oddi, allowing passage of extraction balloons and baskets to remove stones. Success rates exceed ninety percent for stones smaller than 15 mm. Large or impacted stones may require mechanical lithotripsy or cholangioscopy-directed laser or electrohydraulic lithotripsy. Following successful duct clearance, cholecystectomy should be performed to prevent recurrent stone formation, ideally during the same hospitalization. Laparoscopic common bile duct exploration at the time of cholecystectomy offers an alternative single-procedure approach at centers with appropriate expertise.

<image>Panel A: Anatomical diagram of stone locations (cystic duct, common hepatic duct, common bile duct, ampulla) and clinical spectrum from asymptomatic through biliary colic, jaundice, cholangitis, and pancreatitis. Panel B: Laboratory findings showing cholestatic pattern with elevated bilirubin, alkaline phosphatase, and GGT, with mild transaminase elevation. Panel C: Imaging comparison of ultrasound showing dilated common bile duct, MRCP filling defect, EUS appearance, and ERCP fluoroscopic image. Panel D: Management algorithm from diagnosis (MRCP or EUS) through ERCP with sphincterotomy and stone extraction to cholecystectomy, with alternatives for large stones.</image>

Acute Cholangitis

Acute cholangitis represents infection of the biliary tree, occurring when bacteria proliferate in obstructed bile. This constitutes a medical and procedural emergency requiring prompt recognition, antibiotics, and biliary decompression.

Pathophysiology requires two elements: biliary obstruction and bacterial presence. Choledocholithiasis causes approximately eighty percent of cases. Other causes include malignant obstruction, benign strictures, and complications of biliary procedures. Obstruction elevates intrabiliary pressure, disrupting the normal blood-bile barrier and allowing bacterial translocation into the systemic circulation. Common organisms include Escherichia coli (most frequent), Klebsiella species, Enterococcus species, and anaerobes (Bacteroides, Clostridium). In healthcare-associated cholangitis, resistant organisms including Pseudomonas and extended-spectrum beta-lactamase producers may be involved.

Clinical features classically follow Charcot's triad: fever with chills (present in approximately ninety-five percent), right upper quadrant pain (eighty percent), and jaundice (eighty percent). All three components appear in fifty to seventy percent of patients. When cholangitis progresses to septic shock, Reynold's pentad adds hypotension and altered mental status to Charcot's triad, indicating suppurative cholangitis requiring emergency intervention.

The Tokyo Guidelines classify cholangitis severity to guide management intensity. Grade I (mild) cholangitis responds to initial antibiotic therapy. Grade II (moderate) does not respond to initial antibiotics but lacks organ dysfunction, requiring early biliary drainage. Grade III (severe) includes organ dysfunction manifested as cardiovascular instability, altered consciousness, respiratory failure, renal impairment, hepatic dysfunction, or coagulopathy, demanding emergency biliary drainage.

Treatment follows a structured approach. Resuscitation with intravenous fluids and vasopressors if needed addresses sepsis. Broad-spectrum antibiotics targeting biliary pathogens should be initiated immediately; appropriate regimens include piperacillin-tazobactam, or ciprofloxacin plus metronidazole, or a carbapenem for severe or healthcare-associated cases. Biliary drainage is essential for source control. ERCP with sphincterotomy and stone extraction or stent placement is the preferred approach, achieving drainage in over ninety percent of cases. When ERCP fails or is unavailable, percutaneous transhepatic cholangiography with drainage provides an alternative. Surgical drainage is rarely necessary with modern endoscopic and percutaneous techniques but remains an option when other approaches fail.

Timing of drainage correlates with severity. Grade I cholangitis may receive initial antibiotic therapy with drainage performed when convenient (within 24-48 hours). Grade II requires early drainage within 24 hours. Grade III demands emergency drainage as soon as the patient can be stabilized, ideally within hours of presentation.

<image>Panel A: Pathophysiology diagram showing biliary obstruction causing elevated intrabiliary pressure, disrupted blood-bile barrier, bacterial translocation, and systemic infection with common organisms listed. Panel B: Clinical presentation with Charcot's triad (fever, RUQ pain, jaundice) and progression to Reynold's pentad adding hypotension and altered mental status. Panel C: Tokyo Guidelines severity grading showing Grade I (responds to antibiotics), Grade II (no organ dysfunction but refractory), and Grade III (organ dysfunction) with specific criteria. Panel D: Treatment algorithm with drainage timing by severity grade (24-48 hours, within 24 hours, emergency) and drainage methods (ERCP, percutaneous transhepatic, surgical).</image>

Acalculous Cholecystitis

Acalculous cholecystitis, representing five to ten percent of acute cholecystitis cases, occurs in the absence of gallstones and typically affects critically ill patients. Recognition is challenging because classic symptoms may be obscured by the patient's underlying condition.

Risk factors center on critical illness and biliary stasis. Severely ill ICU patients with sepsis, trauma, burns, or major surgery are at highest risk. Prolonged fasting or total parenteral nutrition eliminates CCK-mediated gallbladder contraction. Mechanical ventilation, opioid use, and vasopressor administration all impair gallbladder motility. Hypoperfusion from shock states causes mucosal ischemia.

Pathophysiology differs from calculous cholecystitis. Without stone obstruction, the primary insults are gallbladder stasis and ischemia. Concentrated bile in a stagnant gallbladder causes direct mucosal injury. Simultaneously, systemic hypoperfusion compromises gallbladder wall perfusion. The combination produces inflammation that may progress rapidly to gangrene and perforation. The thin-walled, poorly vascularized gallbladder is particularly vulnerable in shock states.

Clinical features are often subtle or masked by critical illness. Unexplained fever, sepsis, or clinical deterioration in an ICU patient should prompt consideration of acalculous cholecystitis. Right upper quadrant tenderness may be present but is difficult to assess in sedated or intubated patients. Leukocytosis and liver enzyme elevation provide supportive but nonspecific evidence.

Diagnosis requires high clinical suspicion and imaging. Ultrasound findings include gallbladder distension (hydrops), wall thickening exceeding 3 mm, pericholecystic fluid, and sludge (echogenic bile), but importantly no stones are visualized. HIDA scan may demonstrate non-visualization of the gallbladder if cystic duct dysfunction is present. CT scanning can reveal similar findings along with complications. The challenge lies in distinguishing true acalculous cholecystitis from incidental gallbladder findings in a patient with another source of sepsis.

Management in critically ill patients typically involves percutaneous cholecystostomy rather than immediate surgery. Image-guided placement of a drainage catheter into the gallbladder decompresses the organ and allows recovery without the substantial surgical risk of operating on an unstable patient. Broad-spectrum antibiotics cover polymicrobial infection. Once the patient stabilizes, interval cholecystectomy can be performed. In patients who improve dramatically with cholecystostomy and have ongoing contraindications to surgery, the tube may eventually be removed after tract maturation, though recurrence rates are significant without cholecystectomy.

<image>Panel A: Risk factor diagram for acalculous cholecystitis centered on critically ill patients with ICU admission, NPO status, mechanical ventilation, opioid use, vasopressors, and shock states. Panel B: Pathophysiology comparison of calculous (stone obstruction leading to inflammation) versus acalculous (stasis plus ischemia with faster gangrene progression). Panel C: Diagnostic imaging showing ultrasound with distended gallbladder, wall thickening, sludge, pericholecystic fluid, no stones, and HIDA scan non-visualization. Panel D: Management algorithm from ultrasound confirmation through percutaneous cholecystostomy with antibiotics to interval cholecystectomy when stable.</image>

Biliary Strictures and Sphincter of Oddi Dysfunction

Biliary strictures represent abnormal narrowing of the bile ducts from various causes, producing cholestasis and potentially cholangitis if left untreated. Sphincter of Oddi dysfunction causes biliary-type pain through motility abnormalities of the ampullary sphincter.

Benign biliary strictures arise from several etiologies. Post-surgical injury during cholecystectomy represents a common cause, occurring in approximately 0.5 percent of laparoscopic cholecystectomies, typically from thermal injury, clip placement, or direct transection. Chronic pancreatitis can produce stricture of the intrapancreatic common bile duct through fibrotic encasement. Primary sclerosing cholangitis causes multifocal stricturing of intrahepatic and extrahepatic ducts. IgG4-related disease produces inflammatory strictures that may mimic malignancy. Anastomotic strictures occur following liver transplantation or biliary reconstruction.

Bile duct injury during cholecystectomy merits special attention given its frequency and consequences. Minor injuries include cystic duct stump leaks, which typically present with bile leak after surgery and respond to ERCP with stenting. Major injuries involving the common bile duct or hepatic ducts may require complex surgical reconstruction with hepaticojejunostomy. Recognition during surgery allows immediate repair with better outcomes than delayed discovery. Post-operative bile leak, jaundice, or cholangitis should prompt imaging evaluation for biliary injury.

Treatment of benign strictures depends on etiology and location. ERCP with serial balloon dilation and temporary stent placement successfully manages many anastomotic and short post-surgical strictures. Multiple stents placed side-by-side with exchanges every three months for one year achieve the best long-term patency. Strictures refractory to endoscopic therapy require surgical reconstruction, typically hepaticojejunostomy (Roux-en-Y).

Sphincter of Oddi dysfunction describes manometrically demonstrated elevated sphincter pressures or abnormal sphincter motility causing biliary-type pain. The Rome IV criteria classify this condition and its related functional biliary and pancreatic disorders. Type I includes biliary-type pain with dilated common bile duct and elevated liver enzymes, most likely to benefit from sphincterotomy. Type II has pain with either ductal dilation or enzyme elevation but not both. Type III has pain alone without objective abnormalities and is now classified as functional biliary pain rather than sphincter dysfunction; invasive investigation and sphincterotomy should be avoided in these patients due to poor outcomes and procedural risks. Endoscopic sphincterotomy is appropriate for Type I, considered for Type II after careful evaluation, and contraindicated for Type III.

<image>Panel A: Benign biliary stricture etiologies including post-surgical injury, chronic pancreatitis, PSC, IgG4-related disease, and anastomotic strictures after transplant. Panel B: Bile duct injury classification (minor cystic duct leak versus major CBD transection) with management approaches (ERCP stent versus surgical reconstruction). Panel C: Endoscopic treatment of strictures with balloon dilation, stent placement, and multiple stent technique for refractory cases. Panel D: Sphincter of Oddi dysfunction Rome IV classification showing Type I (sphincterotomy beneficial), Type II (consider sphincterotomy), and Type III (functional biliary pain, avoid ERCP) with manometry tracing.</image>

Biliary Tract Malignancies

Biliary tract malignancies include gallbladder cancer, cholangiocarcinoma, and ampullary carcinoma. These tumors are relatively uncommon but carry poor prognosis, particularly when diagnosed at advanced stages.

Gallbladder carcinoma is the most common biliary malignancy, with incidence of one to two per 100,000 population. Risk factors include chronic gallstone disease (present in seventy-five to ninety percent of cases, though cancer develops in only one to three percent of stone patients), porcelain gallbladder (calcified wall, associated with 10-25% cancer risk), gallbladder polyps exceeding one centimeter, anomalous pancreaticobiliary junction, and chronic infection (typhoid carriers). The vast majority are adenocarcinomas.

Gallbladder cancer is often discovered incidentally during cholecystectomy performed for presumed benign disease, particularly in early stages. Advanced disease presents with right upper quadrant pain, weight loss, jaundice (from direct invasion or nodal compression of the bile duct), and sometimes a palpable mass (Courvoisier sign when the gallbladder is palpable and non-tender in a jaundiced patient, classically associated with malignant obstruction rather than stones). Prognosis is poor, with overall five-year survival below twenty percent, though tumors discovered incidentally at early stage may be cured with radical cholecystectomy including liver resection and lymphadenectomy.

Cholangiocarcinoma arises from bile duct epithelium and is classified by location. Intrahepatic cholangiocarcinoma originates within the liver parenchyma and presents as a hepatic mass. Perihilar cholangiocarcinoma (Klatskin tumor), the most common type (fifty to sixty percent), arises at the confluence of the right and left hepatic ducts. Distal cholangiocarcinoma involves the common bile duct. Risk factors include primary sclerosing cholangitis (strongest association, with ten to fifteen percent lifetime risk), liver fluke infection (endemic in Southeast Asia), choledochal cysts, hepatolithiasis, and chronic hepatitis B or C infection.

Cholangiocarcinoma typically presents with painless jaundice as tumor obstructs bile flow. Weight loss, pruritus, and acholic stools accompany the jaundice. CT or MRI reveals mass lesions or biliary dilation with stricture. ERCP with brushing cytology can confirm diagnosis, though sensitivity is limited. CA 19-9 is often elevated but is neither sensitive nor specific. Treatment depends on resectability. Surgical resection offers the only chance for cure but is possible in only a minority of patients due to local invasion or metastatic disease at presentation. Highly selected patients with perihilar tumors may be candidates for liver transplantation following neoadjuvant chemoradiation. Unresectable disease receives palliative biliary stenting and systemic chemotherapy.

Ampullary carcinoma arises at the ampulla of Vater, where the common bile duct and pancreatic duct enter the duodenum. Its favorable anatomic location causes early symptoms (jaundice from biliary obstruction), enabling earlier diagnosis than pancreatic or bile duct cancer. Diagnosis is made by duodenoscopy with biopsy of the visible papillary lesion. Treatment is pancreaticoduodenectomy (Whipple procedure). Five-year survival of forty to fifty percent significantly exceeds that of pancreatic adenocarcinoma, reflecting the benefit of earlier detection.

<image>Panel A: Three biliary malignancy types with anatomical locations showing gallbladder carcinoma, cholangiocarcinoma subtypes (intrahepatic, perihilar/Klatskin, distal), and ampullary carcinoma at the papilla of Vater. Panel B: Risk factors for each malignancy including gallstones and porcelain gallbladder, PSC with 10-15% cholangiocarcinoma risk, liver flukes, and choledochal cysts. Panel C: Clinical presentation comparison showing gallbladder cancer (incidental finding or advanced jaundice), cholangiocarcinoma (painless jaundice), and ampullary carcinoma (early jaundice enabling earlier detection). Panel D: Staging and treatment with surgical approaches for each type, palliative options for unresectable disease, and five-year survival comparison (ampullary 40-50%, gallbladder less than 20%).</image>

Approach to Jaundice

Jaundice, the clinical manifestation of elevated serum bilirubin, requires systematic evaluation to identify the underlying cause and guide appropriate management. Classification into prehepatic, hepatic, and posthepatic categories provides a logical framework.

Prehepatic jaundice results from increased bilirubin production or impaired hepatic uptake, producing predominantly unconjugated (indirect) hyperbilirubinemia. The conjugating capacity of the liver is overwhelmed or bypassed. Hemolysis (autoimmune, hereditary spherocytosis, sickle cell disease, malaria) represents the classic cause, generating excess bilirubin from accelerated red cell destruction. Ineffective erythropoiesis in conditions like thalassemia produces bilirubin from premature destruction of erythroid precursors. Resorption of large hematomas delivers a bolus of heme for processing. Laboratory findings demonstrate elevated indirect bilirubin with normal liver enzymes, elevated lactate dehydrogenase and decreased haptoglobin in hemolysis, and often reticulocytosis.

Hepatic jaundice arises from hepatocyte dysfunction affecting any step of bilirubin processing, producing mixed or variable hyperbilirubinemia depending on the specific defect. Hepatocellular disease (viral hepatitis, alcoholic hepatitis, drug-induced liver injury, cirrhosis) impairs both conjugation and canalicular excretion. Genetic disorders affect specific steps: Gilbert syndrome involves reduced UGT1A1 activity with mild unconjugated hyperbilirubinemia worsened by fasting or illness; Crigler-Najjar syndrome causes more severe conjugation defects; Dubin-Johnson and Rotor syndromes impair canalicular excretion, producing conjugated hyperbilirubinemia. Laboratory findings in hepatocellular disease include elevated aminotransferases, while synthetic dysfunction manifests as prolonged INR and low albumin.

Posthepatic (obstructive) jaundice results from impaired bile flow, producing predominantly conjugated (direct) hyperbilirubinemia. Conjugated bilirubin, produced normally by hepatocytes, cannot be excreted and regurgitates into blood. Intrinsic obstruction includes choledocholithiasis and biliary strictures. Extrinsic compression from pancreatic head carcinoma, cholangiocarcinoma, or lymphadenopathy represents malignant obstruction. Clinical clues to obstruction include pruritus (bile salt deposition in skin), pale or clay-colored stools (absent fecal urobilinogen), and dark urine (conjugated bilirubin is water-soluble and renally excreted). Laboratory findings demonstrate elevated conjugated bilirubin with markedly elevated alkaline phosphatase and GGT (cholestatic pattern).

The diagnostic approach begins with history and physical examination, followed by laboratory evaluation including fractionated bilirubin and liver enzymes. Transabdominal ultrasound serves as the initial imaging study, answering the key question: is the biliary tree dilated? Dilated ducts indicate obstruction requiring further evaluation with CT or MRCP to characterize the level and nature of obstruction. Non-dilated ducts in a patient with conjugated hyperbilirubinemia suggest intrahepatic cholestasis or early obstruction, prompting evaluation for hepatocellular disease or primary biliary disorders. The pattern of liver enzyme abnormalities (hepatocellular versus cholestatic) provides additional diagnostic guidance.

<image>Panel A: Three-category jaundice classification showing prehepatic (unconjugated, hemolysis), hepatic (mixed, hepatocellular disease and genetic disorders), and posthepatic (conjugated, obstruction) with bilirubin type and causes. Panel B: Clinical features by category including prehepatic (anemia, splenomegaly), hepatic (hepatomegaly, stigmata of liver disease), and posthepatic (pruritus, pale stools, dark urine). Panel C: Laboratory patterns for each category showing characteristic bilirubin fractionation, liver enzyme profiles, and additional markers. Panel D: Diagnostic algorithm flowchart from bilirubin fractionation through ultrasound assessment of ductal dilation to CT/MRCP for obstruction or evaluation for intrahepatic cholestasis.</image>

Summary

Gallstones affect ten to fifteen percent of adults, with cholesterol stones comprising the majority. Risk factors include female sex, obesity, rapid weight loss, and ileal disease. Biliary colic represents transient cystic duct obstruction with self-limited pain under six hours, while acute cholecystitis involves persistent obstruction with inflammation lasting beyond six hours. Murphy's sign, fever, and leukocytosis distinguish cholecystitis from biliary colic.

Tokyo Guidelines stratify cholecystitis severity to guide management: Grade I (mild) benefits from early cholecystectomy within 72 hours, Grade II (moderate) may receive early or delayed surgery, and Grade III (severe with organ dysfunction) requires percutaneous cholecystostomy followed by interval surgery. Complications including gangrenous cholecystitis, emphysematous cholecystitis, and perforation require urgent intervention.

Choledocholithiasis affects ten to fifteen percent of gallstone patients, presenting with cholestatic laboratory abnormalities and potentially causing cholangitis or pancreatitis. MRCP provides non-invasive diagnosis, while ERCP with sphincterotomy offers definitive treatment. Cholangitis demands rapid recognition of Charcot's triad, initiation of antibiotics, and biliary drainage with urgency proportional to severity.

Acalculous cholecystitis occurs in critically ill patients, diagnosed by ultrasound showing inflammation without stones, and typically managed with percutaneous cholecystostomy. Benign biliary strictures arise from surgical injury, chronic pancreatitis, or autoimmune conditions, while sphincter of Oddi dysfunction Type I (with objective abnormalities) responds to sphincterotomy.

Biliary malignancies include gallbladder cancer (associated with chronic stones, poor prognosis), cholangiocarcinoma (perihilar most common, PSC a major risk factor), and ampullary carcinoma (early presentation, relatively better prognosis). Jaundice evaluation distinguishes prehepatic (unconjugated, hemolysis), hepatic (mixed, hepatocellular disease), and posthepatic (conjugated, obstruction) causes through bilirubin fractionation and ultrasound assessment of ductal dilation.

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown